Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Recent advancements in diagnostic tools, surgical treatments, chemotherapies, and molecular targeted therapies that improved the therapeutic...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.643942/full |
id |
doaj-7f2a4e905ff546d99babd5cb991bd880 |
---|---|
record_format |
Article |
spelling |
doaj-7f2a4e905ff546d99babd5cb991bd8802021-04-07T05:14:49ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-04-01910.3389/fcell.2021.643942643942Frontiers of MicroRNA Signature in Non-small Cell Lung CancerXinping Zhu0Masahisa Kudo1Xiangjie Huang2Hehuan Sui3Haishan Tian4Carlo M. Croce5Ri Cui6Ri Cui7Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaComprehensive Cancer Center, Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United StatesCancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaCancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaCancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaComprehensive Cancer Center, Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United StatesCancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaComprehensive Cancer Center, Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United StatesLung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Recent advancements in diagnostic tools, surgical treatments, chemotherapies, and molecular targeted therapies that improved the therapeutic efficacy in NSCLC. However, the 5-years relative survival rate of NSCLC is only about 20% due to the inadequate screening methods and late onset of clinical symptoms. Dysregulation of microRNAs (miRNAs) was frequently observed in NSCLC and closely associated with NSCLC development, progression, and metastasis through regulating their target genes. In this review, we provide an updated overview of aberrant miRNA signature in NSCLC, and discuss the possibility of miRNAs becoming a diagnostic and therapeutic tool. We also discuss the possible causes of dysregulated miRNAs in NSCLC.https://www.frontiersin.org/articles/10.3389/fcell.2021.643942/fullNSCLCmiRNAmiRNA therapeuticscirculatory miRNAsmiRNA dysregulation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xinping Zhu Masahisa Kudo Xiangjie Huang Hehuan Sui Haishan Tian Carlo M. Croce Ri Cui Ri Cui |
spellingShingle |
Xinping Zhu Masahisa Kudo Xiangjie Huang Hehuan Sui Haishan Tian Carlo M. Croce Ri Cui Ri Cui Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer Frontiers in Cell and Developmental Biology NSCLC miRNA miRNA therapeutics circulatory miRNAs miRNA dysregulation |
author_facet |
Xinping Zhu Masahisa Kudo Xiangjie Huang Hehuan Sui Haishan Tian Carlo M. Croce Ri Cui Ri Cui |
author_sort |
Xinping Zhu |
title |
Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer |
title_short |
Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer |
title_full |
Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer |
title_fullStr |
Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer |
title_full_unstemmed |
Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer |
title_sort |
frontiers of microrna signature in non-small cell lung cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cell and Developmental Biology |
issn |
2296-634X |
publishDate |
2021-04-01 |
description |
Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Recent advancements in diagnostic tools, surgical treatments, chemotherapies, and molecular targeted therapies that improved the therapeutic efficacy in NSCLC. However, the 5-years relative survival rate of NSCLC is only about 20% due to the inadequate screening methods and late onset of clinical symptoms. Dysregulation of microRNAs (miRNAs) was frequently observed in NSCLC and closely associated with NSCLC development, progression, and metastasis through regulating their target genes. In this review, we provide an updated overview of aberrant miRNA signature in NSCLC, and discuss the possibility of miRNAs becoming a diagnostic and therapeutic tool. We also discuss the possible causes of dysregulated miRNAs in NSCLC. |
topic |
NSCLC miRNA miRNA therapeutics circulatory miRNAs miRNA dysregulation |
url |
https://www.frontiersin.org/articles/10.3389/fcell.2021.643942/full |
work_keys_str_mv |
AT xinpingzhu frontiersofmicrornasignatureinnonsmallcelllungcancer AT masahisakudo frontiersofmicrornasignatureinnonsmallcelllungcancer AT xiangjiehuang frontiersofmicrornasignatureinnonsmallcelllungcancer AT hehuansui frontiersofmicrornasignatureinnonsmallcelllungcancer AT haishantian frontiersofmicrornasignatureinnonsmallcelllungcancer AT carlomcroce frontiersofmicrornasignatureinnonsmallcelllungcancer AT ricui frontiersofmicrornasignatureinnonsmallcelllungcancer AT ricui frontiersofmicrornasignatureinnonsmallcelllungcancer |
_version_ |
1721536437518598144 |